Zur Rose AG

EQS-News: Zur Rose Group: Notice of an Extraordinary General Meeting to be held on 19 June 2017 and Setting the stage for raising additional funds to accelerate growth

EQS Group-News: Zur Rose Group AG / Key word(s): Miscellaneous
Zur Rose Group: Notice of an Extraordinary General Meeting to be held on 19 June
2017 and Setting the stage for raising additional funds to accelerate growth

30.05.2017 / 07:00
Press Release

Zur Rose Group

- Notice of an Extraordinary General Meeting to be held on 19 June 2017

- Setting the stage for raising additional funds to accelerate growth

As announced at the Annual General Meeting held on 4 May 2017, the Zur Rose
Group is seeking to capitalise on the wide range of growth opportunities offered
by the market to further expand its strong position in the European
pharmaceutical mail-order sector. Against this background, the Board of
Directors is evaluating options for raising additional funds. The options being
considered by UBS and Berenberg on behalf of Zur Rose Group AG include an
initial public offering with a capital increase ("IPO"), further private funding
and also additional debt financing. To set the stage for an IPO, an
Extraordinary General Meeting will be held on 19 June 2017. Shareholder approval
of the business on the agenda would allow Zur Rose Group AG to proceed with an
initial public offering, possibly even this year, if the circumstances are

At the Extraordinary General Meeting, the Board of Directors will propose the
creation of authorised share capital representing 50 per cent of the existing
share capital. In view of an initial public offering, the Board of Directors is
proposing a revision and restatement of the Articles of Association to conform
to the requirements for listed companies and, in particular, also to the
provisions of the Ordinance Against Excessive Compensation in Listed Companies
(Verordnung gegen übermässige Vergütungen bei börsenkotierten
Aktiengesellschaften, VegüV). The revised and restated Articles of Association
would only become effective on completion of an authorised increase in share
capital in connection with an initial public offering by Zur Rose Group AG.

The Notice of the Extraordinary General Meeting and the full draft Articles of
Association can be viewed at www.zurrosegroup.com | Investors & Media | General
Meeting of Shareholders.


Lisa Lüthi, Head of Corporate Communications
Email: lisa.luethi@zurrose.com, telephone: +41 52 724 08 14


Zur Rose Group

Operating under the "Zur Rose" and "DocMorris" brands, the Swiss-based Zur Rose
Group is Europe's leading online pharmacy and one of Switzerland's foremost
wholesale suppliers to medical practitioners. Through its business model, it
helps to ensure safe, reliable and high-quality pharmaceutical care, while also
excelling in developing innovative medicines management services to increase the
effectiveness of the medication process. This creation of added value, the
strong focus on patients and the commitment to supply pharmaceuticals at low
cost make the Group an important strategic partner for healthcare providers,
payers and industry.

The Zur Rose Group is headquartered in Frauenfeld, from where it is also serves
the Swiss market. In Germany and Austria, the Group operates through
subsidiaries in Heerlen (Netherlands) and Halle an der Saale (Germany).
Furthermore, it holds a majority interest in BlueCare in Winterthur, the leading
provider of networking systems in the Swiss healthcare market. Employing more
than 800 people at its various locations, the Zur Rose Group generated revenue
of CHF 880 million in 2016.

Zur Rose Group AG's shares (Swiss security no. 4261528, ISIN CH0042615283) are
traded on the Berner Kantonalbank's OTC-X, Zürcher Kantonalbank's eKMU-X and
Lienhardt & Partners Private Bank Zurich Ltd's trading platforms. The CHF 50
million corporate bond issued in November 2012 for the purpose of financing the
DocMorris acquisition is listed on the SIX Swiss Exchange (Swiss security no.
19972936, ISIN CH0199729366, ticker symbol ZRO12). zurrosegroup.com


This communication may contain statements about the future that use words such
as, for example, "believe", "assume", "expect" and other similar expressions.
Such statements about the future are subject to risks, uncertainties, and other
factors, which can cause the true results of the company to differ significantly
from that which is expressly or implicitly assumed in these statements. In view
of these uncertainties, the reader should not depend on this type of statement
about the future. The company gives no undertaking whatever to update such
statements regarding the future, or to adapt them to future events or

End of Corporate News

Language: English

Company:  Zur Rose Group AG

          Walzmühlestrasse 60

          8500 Frauenfeld


Phone:    +41 52 724 08 14

Internet: www.zurrosegroup.com

ISIN:     CH0199729366, CH0042615283

Listed:   SIX Swiss Exchange


End of News EQS Group News Service


578295  30.05.2017 

Weitere Meldungen: Zur Rose AG

Das könnte Sie auch interessieren: